ArticleCureus2024
Mal de Debarquement Syndrome: A Case Presentation of a Vestibular Enigma.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mal de Debarquement (MdD) is a rare vestibular disorder characterized by a rocking or swaying sensation following passive motion exposure, such as boat or airplane travel. The etiology and pathogenesis are unknown. Due to a lack of clinical awareness and research, it is underrecognized and misdiagnosed. We present a case of a 37-year-old male with classic MdD symptoms following an amusement park boat ride. Along with normal evaluations, including neurological and vestibular tests, the patient experienced relief with clonazepam, aligned with current management strategies. MdD's impact extends beyond physical symptoms, with studies showing significant economic and psychological burdens associated with the condition. Therefore, it is important to recognize MdD as a missed diagnosis that can potentially result in prolonged and debilitating symptoms that may require management with selective serotonin reuptake inhibitors (SSRIs), transcranial magnetic stimulation, or vestibular rehabilitation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.